LOGIN
AAOS2017: Triamcinonlone has higher rate of resolution for trigger finger vs dexamethasone
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
69 patients with trigger finger were randomized to treatment with either triamcinolone injection or dexamethasone injection. Patients were followed up at 6 weeks, 12 weeks, and 6 months for symptom resolution. Repeat injections were offered in cases of persistent or recurrent symptoms. During follow-up, fewer patients of the triamcinolone group required repeat injection compared to the dexamethaso...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.